|
1
|
Tiezzi DG, De Andrade JM, Cândido dos Reis
FJ, Marana HR, Ribeiro-Silva A, Tiezzi MG and Pereira AP: Apoptosis
induced by neoadjuvant chemotherapy in breast cancer. Pathology.
38:21–27. 2006.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Khan M, Rasul A, Yi F, Zhong L and Ma T:
Jaceosidin induces p53-dependent G2/M phase arrest in U87
glioblastoma cells. Asian Pac J Cancer Prev. 12:3235–3238.
2011.PubMed/NCBI
|
|
3
|
Rasul A, Khan M, Yu B, Ma T and Yang H:
Xanthoxyletin, a coumarin induces S phase arrest and apoptosis in
human gastric adenocarcinoma SGC-7901 cells. Asian Pac J Cancer
Prev. 12:1219–1223. 2011.PubMed/NCBI
|
|
4
|
Ding M, Shao Y, Sun D, Meng S, Zang Y,
Zhou Y, Li J, Lu W and Zhu S: Design, synthesis, and biological
evaluation of BRD4 degraders. Bioorg Med Chem.
78(117134)2023.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Chrienova Z, Rysanek D, Oleksak P, Stary
D, Bajda M, Reinis M, Mikyskova R, Novotny O, Andrys R, Skarka A,
et al: Discovery of small molecule mechanistic target of rapamycin
inhibitors as anti-aging and anti-cancer therapeutics. Front Aging
Neurosci. 14(1048260)2022.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Davidson NE, O'Neill AM, Vukov AM, Osborne
CK, Martino S, White DR and Abeloff MD: Chemoendocrine therapy for
premenopausal women with axillary lymph node-positive, steroid
hormone receptor-positive breast cancer: Results from INT 0101
(E5188). J Clin Oncol. 23:5973–5982. 2005.PubMed/NCBI View Article : Google Scholar
|
|
7
|
International Breast Cancer Study Group.
Colleoni M, Gelber S, Goldhirsch A, Aebi S, Castiglione-Gertsch M,
Price KN, Coates AS and Gelber RD: Tamoxifen after adjuvant
chemotherapy for premenopausal women with lymph node-positive
breast cancer: International breast cancer study group trial 13-93.
J Clin Oncol. 24:1332–1341. 2006.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Morales L, Canney P, Dyczka J, Rutgers E,
Coleman R, Cufer T, Welnicka-Jaskiewicz M, Nortier J, Bogaerts J,
Therasse P, et al: Postoperative adjuvant chemotherapy followed by
adjuvant tamoxifen versus nil for patients with operable breast
cancer: A randomised phase III trial of the European organisation
for research and treatment of cancer breast group. Eur J Cancer.
43:331–340. 2007.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Fukuda M, Yamaguchi S, Ohta T, Nakayama Y,
Ogata H, Shimizu K, Nishikawa T, Adachi Y and Fukuma E: Combination
therapy for advanced breast cancer: Cyclophosphamide, doxorubicin,
UFT, and tamoxifen. Oncology (Williston Park). 13 (7 Suppl
3):S77–S81. 1999.PubMed/NCBI
|
|
10
|
Hupperets PS, Wils JA, Volovics L,
Schouten LJ, Fickers MM, Bron HN, Jager JJ, de Jong JM and Blijham
GH: Adjuvant chemo-hormonal therapy with cyclophosphamide,
doxorubicin and 5-fluorouracil (CAF) with or without
medroxyprogesterone acetate (MPA) for node-positive cancer
patients, update at 12 years follow up. Breast. 10:35–37.
2001.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Gordon NH, Silverman P, Lasheen W, Meinert
J and Siminoff LA: Thirty-year follow-up of chemo/hormonal therapy
in node-positive breast cancer. Breast Cancer Res Treat.
102:301–312. 2007.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Alramadhan M, Ryu JM, Rayzah M, Nam SJ,
Kim SW, Yu J, Lee SK, Bae SY, Park S, Paik HJ and Lee JE: Goserelin
plus tamoxifen compared to chemotherapy followed by tamoxifen in
premenopausal patients with early stage-, lymph node-negative
breast cancer of luminal A subtype. Breast. 30:111–117.
2016.PubMed/NCBI View Article : Google Scholar
|
|
13
|
De La Cruz LM, Harhay MO, Zhang P and
Ugras S: Impact of neoadjuvant chemotherapy on breast cancer
subtype: Does subtype change and, if so, how?: IHC profile and
neoadjuvant chemotherapy. Ann Surg Oncol. 25:3535–3540.
2018.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Zhang N, Moran MS, Huo Q, Haffty BG and
Yang Q: The hormonal receptor status in breast cancer can be
altered by neoadjuvant chemotherapy: a meta-analysis. Cancer
Invest. 29:594–598. 2011.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Luengo-Gil G, García-Martínez E,
Chaves-Benito A, Conesa-Zamora P, Navarro-Manzano E,
González-Billalabeitia E, García-Garre E, Martínez-Carrasco A,
Vicente V and Ayala de la Peña F: Clinical and biological impact of
miR-18a expression in breast cancer after neoadjuvant chemotherapy.
Cell Oncol (Dordr). 42:627–644. 2019.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Paulsen GH, Strickert T, Marthinsen AB and
Lundgren S: Changes in radiation sensitivity and steroid receptor
content induced by hormonal agents and ionizing radiation in breast
cancer cells in vitro. Acta Oncol. 35:1011–1019. 1996.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Bravatà V, Cava C, Minafra L, Cammarata
FP, Russo G, Gilardi MC, Castiglioni I and Forte GI:
Radiation-induced gene expression changes in high and low grade
breast cancer cell types. Int J Mol Sci. 19(1084)2018.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Rose HN and McGrath CM: Alpha-lactalbumin
production in human mammary carcinoma. Science. 190:673–675.
1975.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Iselt M, Holtei W and Hilgard P: The
tetrazolium dye assay for rapid in vitro assessment of
cytotoxicity. Arzneimittelforschung. 39:747–749. 1989.PubMed/NCBI
|
|
20
|
Volkova YA, Antonov YS, Komkov AV,
Scherbakov AM, Shashkov AS, Menchikov LG, Chernoburova LI and
Zavarzin IV: Access to steroidal pyridazines via modified
thiohydrazides. RSC Adv. 6:42863–42868. 2016.
|
|
21
|
Singh NP, McCoy MT, Tice RR and Schneider
EL: A simple technique for quantitation of low levels of DNA damage
in individual cells. Exp Cell Res. 175:184–191. 1988.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Reid G, Hübner MR, Métivier R, Brand H,
Denger S, Manu D, Beaudouin J, Ellenberg J and Gannon F: Cyclic,
proteasome-mediated turnover of unliganded and liganded ERalpha on
responsive promoters is an integral feature of estrogen signaling.
Mol Cell. 11:695–707. 2003.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Reid G, Métivier R, Lin CY, Denger S,
Ibberson D, Ivacevic T, Brand H, Benes V, Liu ET and Gannon F:
Multiple mechanisms induce transcriptional silencing of a subset of
genes, including oestrogen receptor alpha, in response to
deacetylase inhibition by valproic acid and trichostatin A.
Oncogene. 24:4894–4907. 2005.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Scherbakov AM, Komkov AV, Komendantova AS,
Yastrebova MA, Andreeva OE, Shirinian VZ, Hajra A, Zavarzin IV and
Volkova YA: Steroidal pyrimidines and dihydrotriazines as novel
classes of anticancer agents against hormone-dependent breast
cancer cells. Front Pharmacol. 8(979)2018.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Semina SE, Scherbakov AM, Vnukova AA,
Bagrov DV, Evtushenko EG, Safronova VM, Golovina DA, Lyubchenko LN,
Gudkova MV and Krasil'nikov MA: Exosome-mediated transfer of cancer
cell resistance to antiestrogen drugs. Molecules.
23(829)2018.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Mruk DD and Cheng CY: Enhanced
chemiluminescence (ECL) for routine immunoblotting: An inexpensive
alternative to commercially available kits. Spermatogenesis.
1:121–122. 2011.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Taylor SC, Berkelman T, Yadav G and
Hammond M: A defined methodology for reliable quantification of
Western blot data. Mol Biotechnol. 55:217–226. 2013.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Butler TAJ, Paul JW, Chan EC, Smith R and
Tolosa JM: Misleading Westerns: Common quantification mistakes in
western blot densitometry and proposed corrective measures. Biomed
Res Int. 2019(5214821)2019.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Kho MC and Parsonnet V: Observations on
the use of 5-fluorouracil in metastatic carcinoma of the breast. J
Newark Beth Isr Hosp. 12:93–100. 1961.PubMed/NCBI
|
|
30
|
Curreri AR and Ansfield FJ: Comparison of
5-fluorouracil and 5-fluoro-2'-deoxyuridine in the treatment of
far-advanced breast and colon lesions. Cancer Chemother Rep.
16:387–388. 1962.PubMed/NCBI
|
|
31
|
Del Mastro L, Poggio F, Blondeaux E, De
Placido S, Giuliano M, Forestieri V, De Laurentiis M, Gravina A,
Bisagni G, Rimanti A, et al: Fluorouracil and dose-dense adjuvant
chemotherapy in patients with early-stage breast cancer (GIM2):
End-of-study results from a randomised, phase 3 trial. Lancet
Oncol. 23:1571–1582. 2022.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Bogush TA, Polezhaev BB, Mamichev IA,
Bogush EA, Polotsky BE, Tjulandin SA and Ryabov AB: Tamoxifen never
ceases to amaze: New findings on non-estrogen receptor molecular
targets and mediated effects. Cancer Invest. 36:211–220.
2018.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Semiglazov VF, Semiglazov VV, Klemtsel AA,
Barash NIu, Zhil'tsova EK, Bozhok AA, Mel'nikova OA, Paltuev RM,
Dashian GA, Petrovskiĭ SG, et al: New results of endocrine therapy
of breast cancer (the role of Aromasin). Vopr Onkol. 50:729–736.
2004.PubMed/NCBI(In Russian).
|
|
34
|
Lukina SS, Burdennyy AM, Zavarykina TM,
Riabchikov DA, Kazubskaya TP, Kruglova MP and Loginov VI: The role
of ESR1 gene polymorphic markers in the development of breast
cancer and resistance to tamoxifen therapy. Bull Exp Biol Med.
170:350–355. 2021.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Jordan VC: 50th anniversary of the first
clinical trial with ICI 46,474 (tamoxifen): Then what happened?
Endocr Relat Cancer. 28:R11–R30. 2021.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Babyshkina N, Vtorushin S, Dronova T,
Patalyak S, Slonimskaya E, Kzhyshkowska J, Cherdyntseva N and
Choynzonov E: Impact of estrogen receptor α on the tamoxifen
response and prognosis in luminal-A-like and luminal-B-like breast
cancer. Clin Exp Med. 19:547–556. 2019.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Anurag M, Punturi N, Hoog J, Bainbridge
MN, Ellis MJ and Haricharan S: Comprehensive profiling of DNA
repair defects in breast cancer identifies a novel class of
endocrine therapy resistance drivers. Clin Cancer Res.
24:4887–4899. 2018.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Wang SC, Chang HS, Tang JY, Farooqi AA,
Kuo YT, Hsuuw YD, Lee JW and Chang HW: Combined treatment with
cryptocaryone and ultraviolet C promotes antiproliferation and
apoptosis of oral cancer cells. Int J Mol Sci.
23(2981)2022.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Chen W, Tang Z, Hu S, Yi X and Wang J:
Ultraviolet C irradiation-induced dehybridization of
double-stranded oligonucleotides: mechanism investigation and
label-free measurement of the photodamage level. Langmuir.
38:15190–15197. 2022.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Bangruwa N, Srivastava M and Mishra D:
CISS-based label-free novel electrochemical impedimetric detection
of UVC-induced DNA damage. ACS Omega. 7:37705–37713.
2022.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Potapovich AI, Kostyuk TV, Shman TV,
Ermilova TI, Shutava TG and Kostyuk VA: DNA repair activation and
cell death suppression by plant polyphenols in keratinocytes
exposed to ultraviolet irradiation. Rejuvenation Res. 26:1–8.
2023.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Muthusamy V and Piva TJ: The UV response
of the skin: A review of the MAPK, NFkappaB and TNFalpha signal
transduction pathways. Arch Dermatol Res. 302:5–17. 2010.PubMed/NCBI View Article : Google Scholar
|
|
43
|
László CF and Wu S: Mechanism of
UV-induced IkappaBalpha-independent activation of NF-kappaB.
Photochem Photobiol. 84:1564–1568. 2008.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Lu W, László CF, Miao Z, Chen H and Wu S:
The role of nitric-oxide synthase in the regulation of UVB
light-induced phosphorylation of the alpha subunit of eukaryotic
initiation factor 2. J Biol Chem. 284:24281–24288. 2009.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Fishelevich R, Zhao Y, Tuchinda P, Liu H,
Nakazono A, Tammaro A, Meng TC, Lee J and Gaspari AA:
Imiquimod-induced TLR7 signaling enhances repair of DNA damage
induced by ultraviolet light in bone marrow-derived cells. J
Immunol. 187:1664–1673. 2011.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Madson JG and Hansen LA: Multiple
mechanisms of Erbb2 action after ultraviolet irradiation of the
skin. Mol Carcinog. 46:624–628. 2007.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Shan Z, Liu L, Shen J, Hao H, Zhang H, Lei
L, Liu F and Wang Z: Enhanced UV resistance role of death
domain-associated protein in human MDA-MB-231 breast cancer cells
by regulation of G2 DNA damage checkpoint. Cell Transplant.
29(963689720920277)2020.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Wu S, Jin C, Lu X, Yang J, Liu Q, Qi M, Lu
S, Zhang L and Cai Y: Bystander effect induced by UVC radiation in
Chinese hamster V79 cells. Photochem Photobiol. 90:837–844.
2014.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Krzywon A and Widel M: Bystander Me45
melanoma cells increase damaging effect in UVC-irradiated cells.
Photochem Photobiol. 95:1019–1028. 2019.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Eaton BR, Jiang R, Torres MA, Kahn ST,
Godette K, Lash TL and Ward KC: Benefit of adjuvant radiotherapy
after breast-conserving therapy among elderly women with T1-T2N0
estrogen receptor-negative breast cancer. Cancer. 122:3059–3068.
2016.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Yang PS, Chen CM, Liu MC, Jian JM, Horng
CF, Liu MJ, Yu BL, Lee MY and Chi CW: Radiotherapy can decrease
locoregional recurrence and increase survival in mastectomy
patients with T1 to T2 breast cancer and one to three positive
nodes with negative estrogen receptor and positive lymphovascular
invasion status. Int J Radiat Oncol Biol Phys. 77:516–522.
2010.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Chen JX, Zhang WW, Dong Y, Sun JY, He ZY
and Wu SG: The effects of postoperative radiotherapy on survival
outcomes in patients under 65 with estrogen receptor positive
tubular breast carcinoma. Radiat Oncol. 13(226)2018.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Hughes KS, Schnaper LA, Berry D,
Cirrincione C, McCormick B, Shank B, Wheeler J, Champion LA, Smith
TJ, Smith BL, et al: Lumpectomy plus tamoxifen with or without
irradiation in women 70 years of age or older with early breast
cancer. N Engl J Med. 351:971–977. 2004.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Chesney TR, Yin JX, Rajaee N, Tricco AC,
Fyles AW, Acuna SA and Scheer AS: Tamoxifen with radiotherapy
compared with Tamoxifen alone in elderly women with early-stage
breast cancer treated with breast conserving surgery: A systematic
review and meta-analysis. Radiother Oncol. 123:1–9. 2017.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Steelman LS, Navolanic P, Chappell WH,
Abrams SL, Wong EW, Martelli AM, Cocco L, Stivala F, Libra M,
Nicoletti F, et al: Involvement of Akt and mTOR in
chemotherapeutic- and hormonal-based drug resistance and response
to radiation in breast cancer cells. Cell Cycle. 10:3003–3015.
2011.PubMed/NCBI View Article : Google Scholar
|
|
56
|
Jang H, Baek J, Nam KS and Kim S:
Determination of the optimal time for tamoxifen treatment in
combination with radiotherapy. Int J Oncol. 49:2147–2154.
2016.PubMed/NCBI View Article : Google Scholar
|
|
57
|
Luzhna L, Lykkesfeldt AE and Kovalchuk O:
Altered radiation responses of breast cancer cells resistant to
hormonal therapy. Oncotarget. 6:1678–1694. 2015.PubMed/NCBI View Article : Google Scholar
|
|
58
|
Semina SE, Scherbakov AM, Kovalev SV,
Shevchenko VE and Krasil'nikov MA: Horizontal transfer of tamoxifen
resistance in MCF-7 cell derivates: Proteome study. Cancer Invest.
35:506–518. 2017.PubMed/NCBI View Article : Google Scholar
|
|
59
|
Khatpe AS, Adebayo AK, Herodotou CA, Kumar
B and Nakshatri H: Nexus between PI3K/AKT and estrogen receptor
signaling in breast cancer. Cancers (Basel). 13(369)2021.PubMed/NCBI View Article : Google Scholar
|
|
60
|
Golden E, Rashwan R, Woodward EA, Sgro A,
Wang E, Sorolla A, Waryah C, Tie WJ, Cuyàs E, Ratajska M, et al:
The oncogene AAMDC links PI3K-AKT-mTOR signaling with metabolic
reprograming in estrogen receptor-positive breast cancer. Nat
Commun. 12(1920)2021.PubMed/NCBI View Article : Google Scholar
|
|
61
|
du Rusquec P, Blonz C, Frenel JS and
Campone M: Targeting the PI3K/Akt/mTOR pathway in estrogen-receptor
positive HER2 negative advanced breast cancer. Ther Adv Med Oncol.
12(1758835920940939)2020.PubMed/NCBI View Article : Google Scholar
|
|
62
|
Campbell RA, Bhat-Nakshatri P, Patel NM,
Constantinidou D, Ali S and Nakshatri H: Phosphatidylinositol
3-kinase/AKT-mediated activation of estrogen receptor alpha: A new
model for anti-estrogen resistance. J Biol Chem. 276:9817–9824.
2001.PubMed/NCBI View Article : Google Scholar
|
|
63
|
Du C, Huang D, Peng Y, Yao Y, Zhao Y, Yang
Y, Wang H, Cao L, Zhu WG and Gu J: 5-Fluorouracil targets histone
acetyltransferases p300/CBP in the treatment of colorectal cancer.
Cancer Lett. 400:183–193. 2017.PubMed/NCBI View Article : Google Scholar
|
|
64
|
Zou R, Zhong X, Wang C, Sun H, Wang S, Lin
L, Sun S, Tong C, Luo H, Gao P, et al: MDC1 enhances Estrogen
receptor-mediated transactivation and contributes to breast cancer
suppression. Int J Biol Sci. 11:992–1005. 2015.PubMed/NCBI View Article : Google Scholar
|
|
65
|
Chen J, Liu J, Zeng P, Zhao C, Liu X, Sun
J, Wang J, Fang P, Chen W and Ding J: Estrogen and BRCA1 deficiency
synergistically induce breast cancer mutation-related DNA damage.
Biochem Biophys Res Commun. 613:140–145. 2022.PubMed/NCBI View Article : Google Scholar
|
|
66
|
Ashrafizadeh M, Farhood B, Eleojo Musa A,
Taeb S and Najafi M: Damage-associated molecular patterns in tumor
radiotherapy. Int Immunopharmacol. 86(106761)2020.PubMed/NCBI View Article : Google Scholar
|
|
67
|
Thibodeau PA, Bissonnette N, Bédard SK,
Hunting D and Paquette B: Induction by estrogens of methotrexate
resistance in MCF-7 breast cancer cells. Carcinogenesis.
19:1545–1552. 1998.PubMed/NCBI View Article : Google Scholar
|
|
68
|
Molinari AM, Bontempo P, Schiavone EM,
Tortora V, Verdicchio MA, Napolitano M, Nola E, Moncharmont B,
Medici N, Nigro V, et al: Estradiol induces functional inactivation
of p53 by intracellular redistribution. Cancer Res. 60:2594–2597.
2000.PubMed/NCBI
|
|
69
|
Pairawan S, Zhao M, Yuca E, Annis A, Evans
K, Sutton D, Carvajal L, Ren JG, Santiago S, Guerlavais V, et al:
First in class dual MDM2/MDMX inhibitor ALRN-6924 enhances
antitumor efficacy of chemotherapy in TP53 wild-type hormone
receptor-positive breast cancer models. Breast Cancer Res.
23(29)2021.PubMed/NCBI View Article : Google Scholar
|
|
70
|
Paramanantham A, Jung EJ, Go SI, Jeong BK,
Jung JM, Hong SC, Kim GS and Lee WS: Activated ERK signaling is one
of the major hub signals related to the acquisition of
radiotherapy-resistant MDA-MB-231 breast cancer cells. Int J Mol
Sci. 22(4940)2021.PubMed/NCBI View Article : Google Scholar
|
|
71
|
Sun XY, Li HZ, Xie DF, Gao SS, Huang X,
Guan H, Bai CJ and Zhou PK: LPAR5 confers radioresistance to cancer
cells associated with EMT activation via the ERK/Snail pathway. J
Transl Med. 20(456)2022.PubMed/NCBI View Article : Google Scholar
|
